Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM.

Invest New Drugs. 2012 Dec;30(6):2219-25. doi: 10.1007/s10637-012-9793-y. Epub 2012 Jan 24.

PMID:
22270257
2.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

3.

Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.

Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW.

Cancer Sci. 2013 Apr;104(4):473-80. doi: 10.1111/cas.12098. Epub 2013 Feb 14.

4.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
5.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.

Lancet Oncol. 2013 Jul;14(8):749-59. doi: 10.1016/S1470-2045(13)70163-3. Epub 2013 May 29.

6.

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K.

Invest New Drugs. 2012 Apr;30(2):787-93. doi: 10.1007/s10637-010-9615-z. Epub 2010 Dec 22.

PMID:
21174225
7.

Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.

Brunner S, von Moos R, Mey U, Camenisch Gross U, Freyholdt T, Cathomas R.

Oncol Res Treat. 2014;37(11):646-52. doi: 10.1159/000368313. Epub 2014 Oct 17.

PMID:
25427581
8.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.

Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26.

PMID:
22638623
9.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

10.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.

J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.

PMID:
21300933
11.

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.

Carcinogenesis. 2012 Sep;33(9):1782-90. doi: 10.1093/carcin/bgs203. Epub 2012 Jun 13.

12.

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR.

Clin Colorectal Cancer. 2011 Sep;10(3):171-7. doi: 10.1016/j.clcc.2011.03.022. Epub 2011 Apr 28.

PMID:
21855038
13.

Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).

Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.

Oncology. 2014;87(1):7-20. doi: 10.1159/000360989. Epub 2014 Jun 24.

PMID:
24968756
14.

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.

Lin YL, Liau JY, Yu SC, Ou DL, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL.

PLoS One. 2012;7(11):e50701. doi: 10.1371/journal.pone.0050701. Epub 2012 Nov 28.

15.

mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.

Gordeev SA, Bykova TV, Zubova SG, Bystrova OA, Martynova MG, Pospelov VA, Pospelova TV.

Oncotarget. 2015 Dec 29;6(42):44905-26. doi: 10.18632/oncotarget.6457.

16.

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J.

J Clin Oncol. 2013 Feb 20;31(6):759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26.

PMID:
23182985
17.

The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M.

Clin Colorectal Cancer. 2011 Dec;10(4):333-9. doi: 10.1016/j.clcc.2011.06.004. Epub 2011 Oct 14.

PMID:
22000810
18.

Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.

Cai Z, Ke J, He X, Yuan R, Chen Y, Wu X, Wang L, Wang J, Lan P, Wu X.

Ann Surg Oncol. 2014 Jan;21(1):179-88. doi: 10.1245/s10434-013-3146-8. Epub 2013 Aug 2.

PMID:
23907312
19.

Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY.

Clin Cancer Res. 2009 Jul 1;15(13):4508-13. doi: 10.1158/1078-0432.CCR-08-3179. Epub 2009 Jun 23.

20.

Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.

Zhang J, Jiang W, Liu W, Wu JJ, Song L, Cheng JX, Yao M, Yang LP, Yao DF.

Future Oncol. 2016 Feb;12(4):515-24. doi: 10.2217/fon.15.248. Epub 2016 Jan 18.

PMID:
26776341

Supplemental Content

Support Center